Brean Capital Sees A $300 Million Opportunity For Heron Therapeutics New Drug Launch

0 Comments 5 view(s)
Brean Capital thinks <strong>Heron Therapeutics Inc</strong> (NASDAQ: <a href="http://www.benzinga.com/stock/hrtx#NASDAQ">HRTX</a>) has a $300 million opportunity over the next five years from yet-to-be-launched Sustol.

Latest Ratings for HRTX

Date Firm Action From To
Oct 2016 Brean Capital Assumes Buy
Oct 2016 Jefferies Maintains Buy
Sep 2016 Lake Street Assumes Buy

View More Analyst Ratings for HRTX

View the Latest Analyst Ratings